Thermo Fisher Scientific Inc. 2008 10-K Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2008. Thermo Fisher Scientific Inc. is the world leader in serving science, formed by the 2006 merger of Thermo Electron Corporation and Fisher Scientific International Inc. The company operates through two principal segments: Analytical Technologies (high-end analytical instruments, software, and services) and Laboratory Products and Services (laboratory equipment, chemicals, consumables, and biopharma services). As of December 31, 2008, the company employed approximately 34,500 people and served over 350,000 customers globally.
Key Financial Metrics
| Metric (in millions, except per share) | 2008 | 2007 |
|---|---|---|
| Revenues | $10,498.0 | $9,746.4 |
| Operating Income | $1,229.4 | $974.4 |
| Operating Margin | 11.7% | 10.0% |
| Net Income | $994.2 | $761.1 |
| Diluted EPS | $2.29 | $1.72 |
| Cash Flow from Operations | $1,420.2 | $1,483.5 |
| Total Debt (Outstanding) | $2,058.3 | $2,195.2 |
| Working Capital | $2,805.7 | $1,763.7 |
| Cash and Short-term Investments | $1,288.0 | $639.2 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8% ($752 million) driven by a $453 million increase in organic demand, $186 million from acquisitions, and a $113 million favorable currency translation effect. Growth was strong in Asia and moderate in North America.
- Profitability: Operating income increased 26% to $1.23 billion. Margins expanded due to price increases, merger integration savings, productivity improvements, and lower restructuring costs ($37 million in 2008 vs. $91 million in 2007).
- Segment Performance:
- Analytical Technologies: Revenue up 7% to $4.47 billion; Operating income up 16% to $957.1 million.
- Laboratory Products and Services: Revenue up 9% to $6.45 billion; Operating income up 12% to $912.0 million.
- Restructuring: The company recorded net restructuring and other costs of $37 million in 2008, significantly lower than 2007, partially offset by a $19 million gain from the curtailment of a U.S. pension plan.
Guidance, Outlook, and Risks
Outlook and Commentary: Management noted that while the company did not experience a material adverse impact in 2008, the global recession and credit crisis could adversely affect 2009 results. A strengthening U.S. dollar in late 2008 negatively impacted reported revenues by approximately 4% in Q4. Management expects currency translation to negatively affect 2009 revenues by approximately 4% if rates remain at early 2009 levels, potentially reducing EPS by $0.15.
Risks and Contingencies:
- Economic Conditions: Potential for reduced demand, order cancellations, and increased inventory obsolescence due to the global recession.
- Goodwill and Intangibles: The company holds $8.68 billion in goodwill and $1.33 billion in indefinite-lived intangible assets. While no impairment was recorded in 2008, further market deterioration could trigger impairment charges.
- Convertible Debt: Approximately $969 million of outstanding debt is convertible. If converted, the company intends to use its $950 million revolving credit facility to fund cash payments.
- Legal Proceedings: Ongoing patent litigation with Applied Biosystems/MDS Scientific Instruments regarding mass spectrometer systems could result in material damages if the outcome is unfavorable.
Key Facts for Investor Verification
- Convertible Debt Conversion Risk: Verify the status of the $969 million in convertible debt and the company's ability to fund cash settlements via its revolving credit facility if conversion triggers are met.
- Goodwill Impairment Sensitivity: Monitor the company's market capitalization relative to book value and projected cash flows, as a significant decline could necessitate goodwill impairment charges.
- Currency Impact: Assess the impact of the strengthening U.S. dollar on 2009 revenue and earnings, as management explicitly flagged a potential 4% negative translation effect.
- Restructuring Execution: Track the realization of the $34 million in annual cost savings from 2008 restructuring actions and the execution of planned 2009 actions.
- Patent Litigation: Review updates on the mass spectrometer patent infringement lawsuit, as an unfavorable ruling could materially impact financial results.